The IVIVE Chain from Assay Turnover to Human Clearance

From an Assay Signal to an Organ-Level Quantity

In vitro to in vivo extrapolation (IVIVE) connects metabolic activity measured in a laboratory preparation to a quantity suitable for a human pharmacokinetic model. The connection is a chain, not a single conversion: the assay must measure the relevant metabolic process, its rate must be expressed per suitable amount of preparation, incubation binding may need correction, and preparation-level activity must be scaled to the liver. Errors at any link can produce a precise-looking but biologically misleading estimate.

The destination in this chain is an estimate of hepatic intrinsic clearance: the liver’s metabolic capacity in the absence of limitations imposed by hepatic blood flow. It is an input to a hepatic clearance model, not a direct measurement of systemic clearance or of clearance observed in a person. The earlier material on hepatic clearance models explains why the same intrinsic clearance can imply different organ clearance depending on flow and other model assumptions.

Choose the Assay and Define What Was Measured

Two common assay strategies answer related but not identical questions. A substrate-depletion assay follows the loss of parent compound over time. A metabolite-formation assay follows the appearance of one or more products. Either can support an intrinsic-clearance estimate if the measured rate reflects metabolism, the assay is in an interpretable range, and the relevant concentration and preparation amount are known.

The preparation determines what enzymes and cofactors are represented. Liver microsomes are membrane fractions commonly used to study microsomal enzymes; S9 includes a broader mixture of cellular components; and intact hepatocytes retain more cellular organization and can reflect uptake, metabolism, and efflux. Recombinant enzymes isolate a particular enzyme system, but activity in that system is not automatically equivalent to activity in a whole liver. A result must therefore be labelled with its assay and preparation: a rate per milligram of microsomal protein is not interchangeable with a rate per million hepatocytes.

For a measured rate \(v\), total substrate concentration \(C_{\mathrm{tot}}\), and preparation amount \(q\), the assay-basis apparent clearance is

For example, if \(v\) is in amount per minute, \(C_{\mathrm{tot}}\) is in amount per millilitre, and \(q\) is in milligrams of protein, the resulting units are millilitres per minute per milligram of protein. If the preparation amount is a cell count instead, the units must state that cell-count basis. The ratio is meaningful only when the rate and concentration refer to compatible conditions, such as the same incubation and relevant time interval.

Correct for Binding in the Incubation When Needed

A drug may bind nonspecifically to proteins, membranes, or other components of an incubation. If only unbound substrate is available for metabolism, the unbound concentration can be lower than the total concentration used in the assay calculation. Let \(f_{u,\mathrm{inc}}\) denote the fraction unbound in the incubation, so that \(C_u=f_{u,\mathrm{inc}}C_{\mathrm{tot}}\). Under a linear rate relationship with unbound substrate concentration, the apparent and unbound intrinsic clearances are related as follows:

Thus, when the assay clearance was calculated using total concentration, the corresponding unbound clearance is \(CL_{\mathrm{int,u}}=CL_{\mathrm{int,app}}/f_{u,\mathrm{inc}}\). This correction is appropriate only if the fraction unbound is relevant to the assay conditions and the assumed relationship between free concentration and rate is reasonable. If the rate was already calculated using measured unbound concentration, applying the correction again would double-correct the result. If binding is negligible, the correction may be close to one and have little numerical effect.

Incubation binding is distinct from binding in plasma. The incubation correction addresses how much assay substrate is available in the in vitro system; it does not convert intrinsic clearance into plasma-based or observed hepatic clearance. Keeping those quantities separate prevents a binding factor from being applied at the wrong stage.

Scale the Preparation to the Liver

After assay clearance has been placed on the appropriate binding basis, it must be translated from the amount of preparation tested to the amount represented in the liver. The relevant scaling factors depend on the preparation. For microsomes, an appropriate factor may express microsomal protein per gram of liver; for hepatocytes, it may express cells per gram of liver. S9 and recombinant-enzyme data require factors that match their preparation and activity basis. A factor measured for one preparation cannot simply be substituted for another.

For a preparation represented by \(S_{\mathrm{prep}}\) units per gram of liver and a liver mass \(M_{\mathrm{liver}}\), the bookkeeping relationship is

Here \(CL_{\mathrm{int,u,prep}}\) is the unbound clearance per unit of preparation, and the scaling factor and liver mass together represent the corresponding amount of preparation in the whole liver. The product has units of volume per time. This dimensional relationship describes the chain; it does not establish that the chosen factor is biologically appropriate. Selecting and deriving particular microsomal, hepatocyte, S9, or recombinant-enzyme factors requires preparation-specific evidence.

Some extrapolations also require an activity adjustment, for example when an isolated enzyme system is used to represent a larger enzyme pool. Any such factor must be defined on a compatible basis and supported for the intended species and system. Do not multiply by a general enzyme-abundance factor if the reported assay activity or scaling factor already incorporates that abundance.

Assumptions, Checks, and Failure Modes

The chain relies on several assumptions that should be made explicit. The measured turnover must be attributable to the intended metabolic process; the assay rate and substrate concentration must be suitable for the clearance calculation; the preparation amount and scaling factor must refer to compatible units; and any binding correction must reflect the assay conditions. The simple scaling relationship also assumes that preparation-level activity, after the stated factors are applied, represents activity in the target liver. These conditions are not guaranteed just because an equation can be evaluated.

A short dimensional and biological audit often finds problems before model fitting begins. Check that the clearance units per preparation unit cancel with the units in the scaling factor and liver mass. Verify that a microsomal-protein factor is paired with a per-milligram microsomal clearance, not a per-cell clearance. Check whether incubation binding has already been accounted for, and confirm that species, tissue, and preparation definitions match between the assay and scaling inputs. If the scaled estimate is unexpectedly large or small, inspect each factor rather than changing the final value to match an expected answer.

Alternative assay and preparation choices trade breadth for specificity. Substrate depletion can capture loss through multiple pathways but does not by itself identify which pathway caused the loss. Metabolite formation can be more pathway-specific when the product is identified and measured reliably, but a single measured product may not represent all metabolic routes. Intact hepatocytes preserve more cellular context than isolated enzyme preparations, while microsomes or recombinant enzymes can provide more targeted measurements. No preparation is universally best; selection depends on the biological question and on whether its activity can be scaled credibly.

A common mistake is to treat every numerical factor in an IVIVE worksheet as an interchangeable “scaling factor.” The incorrect reasoning is that any factor with a plausible magnitude can convert a per-milligram result to a whole-liver result. The correction is to name the preparation basis and units at every step, then use only a factor that converts that specific basis to the target liver basis. Another pitfall is to interpret a large binding-corrected intrinsic clearance as a large observed hepatic clearance. The correction is to keep the assay-derived intrinsic quantity distinct from the organ-clearance prediction made with a hepatic model.